A detailed history of Amalgamated Bank transactions in 89bio, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,669 shares of ETNB stock, worth $16,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,669
Previous 2,669 -0.0%
Holding current value
$16,494
Previous $21,000 4.76%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$8.13 - $13.77 $49,446 - $83,749
-6,082 Reduced 69.5%
2,669 $31,000
Q4 2023

Feb 06, 2024

SELL
$6.66 - $16.03 $4,129 - $9,938
-620 Reduced 6.62%
8,751 $98,000
Q2 2023

Aug 11, 2023

BUY
$14.15 - $22.03 $132,599 - $206,443
9,371 New
9,371 $177,000
Q2 2022

Aug 15, 2022

SELL
$2.09 - $4.02 $2,562 - $4,928
-1,226 Closed
0 $0
Q1 2022

Jun 30, 2022

BUY
$3.45 - $14.99 $4,229 - $18,377
1,226 New
1,226 $5,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $287M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.